Ipca Laboratories in marketing alliance with Ranbaxy for US sales
21 September 2006
Ranbaxy is engaged in the sale and distribution of generic and branded prescription products in the US healthcare system.
Through this alliance, Ipca will develop a number of generic prescription pharmaceutical products, which will be marketed by Ranbaxy in the US. Ranbaxy will file for regulatory approval and initially support manufacturing of these products.
The first product to be launched under this alliance will be furosemide tablets 20mg, 40mg, and 80mg which received US FDA approval on September 18, 2006. In the future, Ipca will manufacture such products utilising its facilities in India. Most of these products will be supported using the company's DMF-approved 'active pharmaceutical ingredients' (APIs).
Ranbaxy will commercialise these products in the US market through its marketing and distribution network.
IPCA is setting up a new formulations manufacturing facility that meets US regulatory requirements at the special economic Zone in Indore at a capital investment of approximately Rs60 crore.